

# Good Clinical Practice (GCP) and study specific training for the GENVASC Study

GCP component, endorsed by the Clinical Research Network: East Midlands Training and Development Lead



#### Introduction



Clinical Research Network East Midlands

Study background and summary

**Study Conduct** 

GCP background and principles

The Process of Informed Consent

Study Set-up

# NHS National Institute for Health Research

## Study Background

Clinical Research Network
East Midlands

- Coronary artery disease (CAD) is one of the commonest cause of premature death and disability in the UK
- Lifestyle factors contribute to risk of CAD and risk scores are used to classify an individual's risk and target primary prevention measures
- Improving accuracy of risk categorisation is a high priority
- Inheritance plays an important role
- Significant progress has been made in identifying individual genetic variants that affect risk of CAD
- Framework for testing whether adding genetic information in the form of a genetic risk score (GRS) can improve current risk prediction of CAD
- The NHS Health Check Programme provides ideal opportunity to establish a large and representative cohort
- Adopted onto NIHR portfolio
- Led by Professor Nilesh Samani and run by Leicester Cardiovascular BRU





#### **Objective**

 To determine if the addition of genetic information can improve risk prediction of CAD

#### **Target population**

All patients attending for the NHS Health Check

#### Inclusion criteria

- 40 to 74 years inclusive
- Able to give informed consent

#### **Exclusion**

- Known history of CVD
- Known history of blood transmissible infection (e.g. Hep B, HIV)

#### **Duration of recruitment and sample size**

10 years (end date 2022) with a target sample size > 30,000



# GCP BACKGROUND AND PRINCIPLES

At the end of this section you will have an understanding of:

The importance of GCP in relation to clinical research studies

An awareness of the main principles of GCP

## Why do we have standards?



Clinical Research Network
East Midlands

#### **Quality of Data**


Ensure that the data about the drug/intervention is valid and reproducible

Give public assurance that the data is credible

#### **Patient Protection**

To ensure safety of patients participating in study is protected

To ensure that drugs/ interventions we develop are safe for patients in the future.






#### Research Governance Framework

- Introduced to ensure a common quality standard applied to all research in the NHS
- Not law but must be adhered to for all studies conducted within the NHS in England
- Outlines the standards and principles of good governance that apply to all research involving patients, includes clinical and non-clinical research









#### STUDY SET-UP

At the end of this section you will have an understanding of:

The regulatory approvals that need to be in place before a clinical trial can be started in the UK

The responsibilities and/or duties of different members of the research team. Be able to identify a range of essential documents.

The purpose of setting up and maintaining a site file.

The purpose of setting up and maintaining a site file

# NHS National Institute for Health Research

## Responsibilities

Clinical Research Network East Midlands

The Sponsor, Chief Investigator (CI) and Principal Investigator (PI) have defined responsibilities

Your responsibilities

- Study site collaborating agreement
- Abide by RGF, HTA and DPA
- Maintain site file
- Follow procedures outlined in protocol
- Only use approved information documentation
- Personnel appropriately trained and supervised
- Permit supply of clinical data to NIHR Leicester Cardiovascular Biomedical Research Unit
- Permit monitoring at site
- Ensure the safety and well-being of participants
- Report any concerns about study conduct

## **Approvals**



Clinical Research Network
East Midlands

#### A study can only start when you have

- A favourable opinion from a Research Ethics Committee
- Approval from the HRA
- Approval from local Trust/Organisation
- Plus any other relevant approval: i.e. MHRA in case of a drug study and/or Sponsor green light

#### **Essential documents**



Clinical Research Network
East Midlands

These are documents which permit the evaluation of the conduct of a trial and quality of data produced

Demonstrate compliance with GCP and regulatory requirements e.g.

- Protocol
- Approval documentation
- Information sheet/consent form
- Relevant correspondence
- CV's of personnel involved in study

Section 8 of E6 document provides full details (ICH Guidelines for GCP)

#### Site file



Clinical Research Network
East Midlands

All essential documents are stored in designated file

Kept in designated place and maintained by designated person

- Secure area
- Limit access
- Protect from damp, fire etc.
- Provided at start of trial and maintained throughout
- File chronologically with most recent uppermost
- Label superseded documents but do not destroy them

#### **Archive**

- Minimum 5 years
- Stored securely, adequately protected, controlled access



#### Protocol amendments

Clinical Research Network
East Midlands

Substantial amendments require a favourable opinion from the REC, HRA and local Trust/Organisation before they can be implemented

#### Except where urgent safety measures need to be taken

Amendments may result in changes to other essential documents (e.g. PIS/ICF)

New versions must not be used until appropriate approvals are obtained

#### Version control

All study documents must be version controlled



#### **INFORMED CONSENT**

At the end of this section you will:

Understand your responsibilities in the consent process

#### What is informed consent?



Clinical Research Network
East Midlands

- ICH-GCP E6 Document 1.28 (1996)
- A process by which a subject voluntarily confirms
  his/her willingness to participate in a trial, after having
  been informed of all aspects of the trial that are
  relevant to the subjects decision to participate.
  Informed consent is documented by means of a
  written, signed and dated Informed Consent Form.

In order to be valid consent should be

- Voluntary
- Informed
- Competent

#### National Institute for Health Research

Clinical Research Network

East Midlands

The process of informed consent

At practice opportunistic or NHS HC appointment/NHS HC Mailshot Crib sheet, Abbreviated information (opportunistic/NHS HC appointment) or Full information if NHS HC Mailshot

Introduce study idea

Provide written and verbal information

Time to consider study and answer questions

Agreement to proceed by signed and dated consent form

Before any trial related procedure take place



#### Witnessed consent process

Clinical Research Network
East Midlands

The witnessed process can be used opportunistically when patients attend for a clinical visit and have a NHS Health Check

or when they attend specifically for a NHS Health Check

- Discuss concept of study
- If interested provide verbal information

#### Provide information



Clinical Research Network
East Midlands

#### Verbal information

#### Key points to relay to participant

- Purpose
- Voluntary/right to withdraw/will not effect their care
- What will they have to do: consent, blood sample (DNA), permit use
  of data
- Storage of samples and data
- Confidentiality
- Contact/further information
- Crib sheet available: section 1 of site file

# Witnessed consent process - Providing further information



Clinical Research Network
Fast Midlands

#### Written information

- Provide the participant with the abbreviated participant information sheet (version 3 12/09/13) to read prior to consent
- Provide detailed participant information leaflet (version 4 12/09/13) to take home and read later
- Only use Information sheet and consent form approved by REC
- Must not be changed except by formal amendment
- Multiple languages available

## Information (cont.)



Clinical Research Network
Fast Midlands

Establish level of understanding

Mental capacity act (2005)

A person is able to make a decision for themselves if they are able to Understand information relevant to decision

- Retain the information
- Use or weigh the information
- Communicate their decision (by any means)

Answer questions

Provide time to consider participation

Samples not analysed for 30 days to allow more time to consider participation

## Agreement to proceed



Clinical Research Network
East Midlands

Informed Witnessed Consent Sheet
Produced from electronic patient record: Version 4.2 (12/09/13)

- Relay each point verbally
- Participant to initial boxes (not tick)
- Participant to print name, sign and personally date
- Researcher to print name, position, sign and date

#### Consent form filed with Information Sheet

- Original in site file
- Copy in primary care records
- Copy to participant
- Copy with sample

## Optional consent



Clinical Research Network East Midlands

Optional consent field number 7: to be contacted in the future for potential participation in additional studies

 Lack of consent for this aspects does not preclude participation into study

Participant to **initial box** to consent or **cross box** if they do not consent to this optional element





		i		Research	
	GENVASC Study NETICS AND THE VASCULAR HEALTH CHE	Patient name, address, i	Date of Birth (or ID label)		
	NSENT SHEET FOR PARTICIPANTS (12 <sup>TH</sup> SEPTEMBER 2013)		Study Number:		
1.	I have read and understood the Abbreviated P September 2013 and been given the Participan September 2013.	articipant Information S			
2.	I agree to donate blood samples, and allow their use in cardiovascular research (including DNA research). I understand that my donation is voluntary and that I will not receive any individual feedback about the samples.				
3.	I agree to my blood samples being stored for fi	uture cardiovascular res	earch.		
4.	I agree to information from my medical record that my identity will be protected and my med	lical care remains confid	ential.		
		lical care remains confid	ential.		
5.	that my identity will be protected and my med  I understand the Research Sponsor and UK Aut of the research  I agree that future details of my medical situat my NHS number.	lical care remains confic thorities may access my ion may be obtained fro	ential. records to audit the cond om database searches usin	luct	
5.	that my identity will be protected and my med undestand the Research Sponsor and UK Auf of the research  lagree that future details of my medical situat my NHS number.  Please <u>initial</u> the statement belo	lical care remains confic thorities may access my ion may be obtained fro w to indicate you agree	ential.  records to audit the cond  m database searches usir  or X to indicate you disa	luct ng gree	
5.	that my identity will be protected and my med  I understand the Research Sponsor and UK Aut of the research  I agree that future details of my medical situat my NHS number.	thorities may access my ion may be obtained fro w to indicate you agree ig able to contact me in	ential.  records to audit the cond  m database searches usir  or X to indicate you disa,  future if there are suitable	luct gree	
5.	that my identity will be protected and my med I understand the Research Sponsor and UK Auf of the research I agree that future details of my medical situat my NHS number. Please <u>initial</u> the statement belo OPTIONAL I consent to the research team being research projects in might with to participate in	thorities may access my ion may be obtained fro w to indicate you agree g able to contact me in . I understand I am und	records to audit the cond m database searches usir or X to indicate you disa future if there are suitable er no obligation to agree a	luct lg gree e at	
5. 6.	that my identity will be protected and my med of the research Sponsor and UK Auf of the research larger estat future details of my medical situat my NHS number.  Please initial the statement belo OPTIONAL I consent to the research team bein research projects I might wish to participate in the time of the request. My email address is:	ical care remains confic thorities may access my ion may be obtained for w to indicate you agree ag able to contact me in . I understand I am und sture) MUST BE HAND V	records to audit the cond m database searches usir or X to indicate you disa future if there are suitable r no obligation to agree :	gree e at	
5.	that my identity will be protected and my med of the research sponsor and UK Auf of the research.  I agree that future details of my medical situat my NHS number.  Please initial the statement belo OPTIONAL I consent to the research tream bein research projects might with to participate in the time of the request. My email address is:  THE FIELDS BELOW (except signal size) (Print Name)	ical care remains conflic thorities may access my ion may be obtained fire w to indicate you agree ag able to contact me in . I understand I am und sture) MUST BE HAND v	ential. records to audit the cond m database searches usir or X to indicate you disa future if there are suitable r no obligation to agree a VRITTEN IN BLOCK CAPITA sesent:	ng gree e e at at (Print Name)	
4. 5. 6. 7.	that my identity will be protected and my medical structure details of my medical structure details of my medical structure my NHS number.  Please initial the statement belong properties of the statement belong the statement projects in might wish to participate in the time of the request. My email address is:  THE FIELDS BELOW (except signal signal than the medical structure my	lical care remains confici thorities may access my ion may be obtained for w to indicate you agree g able to contact me in 1. I understand I am und sture) MUST BE HAND to Person Taking Cor Sign	ential.  records to audit the cond  m database searches usir  or X to indicate you disa,  turne if there are suitable  r no obligation to agree i  veritten in BLOCK CAPIT,  ssent:  tition:	gree e at	
5. 6.	that my identity will be protected and my medical structure details of my medical structure details of my medical structure my NHS number.  Please initial the statement belong protects in might wish to participate in the time of the request. My email address is:  THE FIELDS BELOW (except signal signal than being structure my	lical care remains confici thorities may access my ion may be obtained for w to indicate you agree g able to contact me in 1. I understand I am und htture) MUST BE HAND to Person Taking Cor Sign	ential.  records to audit the cond  m database searches usir  or X to indicate you disa future if there are suitable  re no obligation to agree a  VRITTEN IN BLOCK CAPITA  usent:  ition:  bate:	ng gree e e at at (Print Name)	
5. 6. Pati	that my identity will be protected and my medical structure details of my medical structure details of my medical structure my NHS number.  Please initial the statement belong properties of the statement belong the statement projects in might wish to participate in the time of the request. My email address is:  THE FIELDS BELOW (except signal signal than the medical structure my	ical care remains confic thorities may access my ion may be obtained fire w to indicate you agree g able to contact me in 1 understand I am und ture) MUST BE HAND V. Person Taking Cor Por Sign J. Imple, sheet3: GP medic	ential.  records to audit the cond  m database searches usir  or X to indicate you disa future if there are suitable  re no obligation to agree a  VRITTEN IN BLOCK CAPITA  usent:  ition:  bate:	gree e at	



#### Unwitnessed consent process

Clinical Research Network
East Midlands

To be used in conjunction with postal invite for the NHS Health Check or provided prior to attending NHS Health Check. Patient must have time prior to their appointment to read the detailed participant information sheet

In case of invite via NHS Health Check mail out:

- GP study specific invitation letter can be used (version 1 28/04/14) or the approved paragraph about GENVASC incorporated into the NHS Health Check invitation letter (version 1 21/04/2016)
- Detailed participant information leaflet (version 4 12/09/13) included
- Unwitnessed consent form (version 1.1 12/09/13) included



## Agreement to proceed - Unwitnessed consent process

Clinical Research Network
East Midlands

Patients wishing to take part in the study return completed unwitnessed consent form to healthcare provider (GP, Nurse, HCA or Phlebotomist) when attending for their clinical Health Check appointment

Consent form must be checked for completeness:

- If patient ticks 'no' in any boxes (other than last optional element),
   the consent form is **not valid**
- Check level of understanding and answer any questions
- Copies of consent form required as per witnessed consent process





	National Insti	N tute	S for		
	Health Ro				
The GENVASC Study  GENETICS AND THE VASCULAR HEALTH CHECK PROGRAMME  JIN-WITNESSED CONSENT SHEET FOR PARTICIPANTS V 1.1 12/09/2013  (you are happy to take part complete this form and bring it with you to your next appointment (NHS Health Check or blood est appointment) and give it to the person you see.					
	Please <u>tick</u> the statements to in	Yes	No		
	have read and understood the Participant Information Leaflet version <mark>4.0 dated 12<sup>th</sup> September 013</mark>				
r	agree to donate blood samples, and allow their use in cardiovascular research (including DNA esearch). I understand that my donation is voluntary and that I will not receive any individual eedback about the samples.				
3. 1	agree to my blood samples being stored for future cardiovascular research.				
	agree to information from my medical records being stored and used for research. I understand hat my identity will be protected and my medical care remains confidential.				
	understand the Research Sponsor and UK Authorities may access my records to audit the conduct of the research				
	agree that future details of my medical situation may be obtained from database searches using ny NHS number.				
r	OPTIONAL I consent to the research team being able to contact me in future if there are suitable esearch projects I might wish to participate in. I understand I am under no obligation to agree at the time of the request. My email address is:				
	THE FIELDS BELOW (except signature) MUST BE HAND WRITTEN IN BLOCK CAPITALS				
atient	Name: (Print Name)				
ddress	3:				
own:					
ostcoo	le:				
ate of					
ignatu					
Date: (a	ld/mm/yyyy)				
eiceste lepartr ilenfiel elepho	Sheet1: sample, Sheet2: site file, Sheet3: GP medical notes, Sheet4: patient es about the project can be made to:  It Cardiovascular Biomedical Research Unit.  Ment of Cardiovascular Sciences, Clinical Science Wing.  Id Hospital, Groby Road. Leicester. LE3 9QP. UK  Men Number: 0116 258 3385 email: <a href="https://linicalsciencestry.com/leac.uk">https://linicalsciencestry.com/leac.uk</a> Version 1.1, 12/09/2013				
	Page 1 of 1				

#### Withdrawal



Clinical Research Network East Midlands

All participants must be provided with a copy of withdrawal form (V1 27/04/12)

Participants can withdraw at any time and do not have to provide a reason

Participant that do wish to withdraw complete withdrawal form and return directly to study team

- Freepost number is included on withdrawal form
- They can indicate whether samples/data already collected can be used or destroyed

Document in patient notes if you are made aware of a withdrawal



## Document the process

Clinical Research Network East Midlands

It is a GCP requirement to document the recruitment process

- Any research activity must be recorded in the participant notes, i.e. recruited, declined or withdrawn consent
- There are generic research read codes for SystMone & EMIS, but free test must be used to reflect that this activity relates to GENVASC
- For example: Participant identified as suitable for the GENVASC study, inclusion/exclusion criteria verified. Information sheet/s and withdrawal form (include version numbers) provided. Study discussed and participant happy to proceed, consent obtained, samples taken.
- Entry will be date and time stamped according to login details



#### STUDY CONDUCT

At the end of this section you will:

Understand how to record study data Know how to record and report a protocol deviation Understand how to process study samples

## Recording data



Clinical Research Network
Fast Midlands

#### Sample bottles & consent forms

- Records must be accurate, legible and complete
- All fields must be completed
- Any change should be initialled and dated
- Strike through original entry with single line (should not obscure original entry)
- Always use black pen
- No abbreviations

#### If its not documented it did not happen





The Protocol must be followed at all times. However, occasionally deviations to the approved protocol may occur. If this happens:

- Record in the patient notes
- Complete the deviation log
- Report to study team



## Data and anonymisation

Clinical Research Network
Fast Midlands

There is a secure GENVASC database, which holds:

- Participant demographics
- Cardiovascular risk factors/scores
- Relevant health information extracted from GP practice databases and hospital systems
- Over time this database is populated with additional relevant participant health information

All participants are allocated a unique study identification number to pseudo-anonymise data

- Data is gathered using participant NHS and System numbers
- Data Sharing Agreements are in place between data controllers and data processors



## Sample collection/processing

Clinical Research Network
East Midlands

Ensure informed consent is obtained **prior** to taking any study samples

Obtain clinical samples in their normal order first, followed by the study samples

Study samples may be drawn separately from a second needle if necessary

The GENVASC study samples are:

- 1 x EDTA 10ml tube
- Label tubes with patient demographics and date
- Store study samples and copy of consent form in a sample bag and place in the fridge for weekly collection




## Portal Registration & Sample Tracking

- When the samples arrive at LCBRC they will be registered on the GENVASC portal
- The Portal will allow for accrual, quarterly reimbursement reporting and document management i.e. recording of study Delegation Log
- https://genvasc.uhl-tr.nhs.uk
- Each member of staff working on the study will be provided with their own Portal login

#### **Portal**



Clinical Research Network East Midlands





#### Sample transit process

Clinical Research Network
East Midlands

- Samples are to be stored in a fridge inside the GENVASC samples container with a copy of the consent form
- Samples are transported on a weekly basis by courier to the LCBRU in a sample transit bag
- If no research sample are obtained, just send the participant consent form
- The courier service will swap the filled transit bag for a new one each week



## **ANY QUESTIONS?**